Regulatory Updates in Japan

Nobumasa NAKASHIMA, Ph.D.
Associate Executive Director (International Programs)
PMDA

The history of MHLW/PMDA -TFDA cooperation for pharmaceuticals and medical devices regulation

Year	Cooperation
2013	Arrangement between the interchange association and the association of east Asian relations for the establishment of the framework of the cooperation on the medical products regulation
	The 1st MHLW/PMDA-TFDA Symposium and bilateral meeting - The symposium takes place every year since 2013 - The bilateral meeting takes place once or twice a year since 2013
2014	The PMDA training programs for the staff members of TFDA -The PMDA training programs take place every year since 2014 Total numbers of seminars and participants ・Seminars 35 *Participants 122 persons (Pharmaceuticals; 109 Medical Devices;13)
2016	Asia-Pacific Economic Cooperation, Life Science Innovation Forum, Regulatory Harmonization Steering Committee (APEC-LSIF-RHSC) /The 1st PMDA-ATC GRM seminar in Taipei
	2016 APEC GRM Regulatory Science Center of Excellence (CoE) Pilot Workshop
	The abridged evaluation scheme of New Drugs at TFDA is revised; - PMDA was regarded as one of 'reference agency' in 'abridged evaluation'.
2017	TFDA is designated as CoE for GRM
	APEC GRM Regulatory Science Center of Excellence (CoE) Workshop take place since 2017 Total numbers of conducted programs; 5
2018	TFDA participates in the ICH as a member. MHLW/PMDA supports TFDA's participation.
	MOC on the field of medical device QMS requirements is concluded
~2021	See the next page
2022	**The 10th Joint Conference of Taiwan and Japan on Medical Products Regulation**
	…what kind of cooperation we will be able to do…

The achievements in Working Groups

New drug WG	
2019	The new drug review scheme is established
Product Registration WG	
2018	Q&A for Challenges in Product Registration Process for Medical Device is issued
2019	Q&A for Challenges in Product Registration Process for Medical Device is amended
2021	Q&A for Challenges in Product Registration Process for Medical Device is amended
	Position Paper for better understanding on product registration framework for Medical Device is issued
Quality Management System WG	
2018	MOC on the field of medical device QMS requirements is concluded
2020	Position Paper on Q&A for the QMS MOC framework for Medical Device is issued

Today's Topics

1.Major regulatory updates in Japan

2.Regulatory Cooperation in Asia

Today's Topics

1.Major regulatory updates in Japan

2.Regulatory Cooperation in Asia

“Principles for the Evaluation of Vaccines Against the Novel Coronavirus SARS-CoV-2”

Background

- To ensure the efficacy and safety of vaccines used in Japan and accelerate vaccine development, the first edition of a guidance summarizing principles for evaluation on non-clinical and clinical study data required for initiation of a clinical study and application for approval was issued on September 2, 2020.
- To date, Appendices 1, 2, 3 and 4 have been issued to supplement the first version in view of the current social circumstance and findings from development of vaccines against SARS-CoV-2 .

Time line

September 2, 2020

Principles for the Evaluation of Vaccines Against the Novel Coronavirus SARS-CoV-2 (first edition) issued

April 5, 2021

Appendix 1_Evaluation of vaccines against variants issued

- It presents principles for evaluation of the efficacy and safety of vaccines against variants in Japan based on knowledge at present and overseas guidance on variant vaccine development in response to a statement of companies which have already granted regulatory approval or emergency use authorization of SARS-CoV-2 vaccine that they will develop vaccines against variants by modifying the existing vaccine.

June 11, 2021

Appendix 2_Ethical Considerations for Subjects in Placebo-Controlled Studies issued

- It presents principles for the ethical consideration given to subjects assigned to a placebo group in ongoing or future clinical studies for development of vaccines against SARS-CoV-2 in view of the circumstance that the Official Vaccination Program in Japan has been initiated and an increasing number of people will be vaccinated in the future.

October 22, 2021

Appendix 3_Principles for the Immunogenicity-based Evaluation of Vaccines Against the Novel Coronavirus

- It presents principles for design of confirmatory clinical trials to evaluate the efficacy of new vaccines against SARS-CoV-2 in unvaccinated subjects on the basis of the immunogenicity in accordance with the ICMRA consensus from an ethical viewpoint since the official vaccination programs have progressed worldwide, making it increasingly difficult to evaluate preventive effects of vaccines on the basis of clinical events (onset, etc.) in placebo-controlled trials.

July 15, 2022

Appendix 4_Principles for the Immunogenicity-based evaluation of variant vaccines modified from parent vaccines and booster vaccines with new active ingredients

- It revises the relevant parts regarding evaluating the quality, efficacy, and safety of vaccines against variants of SARS-CoV-2 in Appendix 1 and presents Japan’s current view on the application of the immunogenicity-based evaluation of vaccines provided in Appendix 3 to vaccines with new active ingredients that are developed for additional doses.

Remote GCP Inspections

- Notification on Remote GCP inspections published in May 2020. ※1
  - It allows PMDA to conduct remote inspections to Sponsors.
  - Confirmation of management on clinical trial sites by sponsor can be done without GCP on-site inspection
- Notification on the method of remote GCP inspections was published in Nov 2020. ※2

- **Implementation policy**
- **Procedure**
- **Consideration for preparing evidence material**
- **Consideration for web conference system**

薬機審長発第 1116002 号
令 和 2 年 11 月 16 日

（別記） 殿

独立行政法人医薬品医療機器総合機構
審 査 セ ン タ ー 長
（ 公 印 省 略 ）

医薬品及び再生医療等製品の適合性調査におけるリモート調査の実施方法について

独立行政法人医薬品医療機器総合機構（以下「機構」という。）が、厚生労働大臣の委託を受けて実施する調査のうち、医薬品及び再生医療等製品の承認申請資料の適合性書面調査及びＧＣＰ実地調査、医薬品の中間評価、再審査及び再評価申請資料の適合性書面調査及びＧＰＳＰ実地調査並びに再生医療等製品の条件及び期限付承認後の承認審査、再審査及び再評価申請資料の適合性書面調査及びＧＰＳＰ実地調査（以下「適合性調査」と総称する。）の実施手続きについては、「医薬品の承認申請資料に係る適合性書面調査及びＧＣＰ実地調

※1 https://www.pmda.go.jp/files/000235011.pdf

※2 https://www.pmda.go.jp/files/000237602.pdf

Q&A on Management of Clinical Trials during COVID-19 Pandemic

Initially published on 27 March, 2020



Sponsors



新型コロナウイルス感染症の影響下での医薬品、医療機器及び再生医療等製品の治験実施に係るQ&Aについて

現在実施中の医薬品、医療機器及び再生医療等製品の治験において、新型コロナウイルス感染症の影響により治験実施計画書の規定及び通常の手順と異なる対応を取らざるを得ない場合は、被験者の安全確保を最優先とした上で、経緯及び対応の記録を残し、その妥当性について説明できるようにしてください。また、実施医療機関において疑義が生じる場合の対応については、まずは治験依頼者と協議・相談してください。

これまでにいただいたお問い合わせに対する回答を、以下にご紹介しますので参考としてください。なお、内容については、今後のお問い合わせに応じて更新いたします。

２０２０年３月２７日作成
２０２０年４月２日更新
２０２０年４月２１日更新

Q１　実施医療機関に来院できない等により、被験者が治験薬、治験機器又は治験製品（以下「治験薬等」という。）を直接受け取れない場合、実施医療機関から被験者宅に配送してよいか。（実施医療機関・治験依頼者）

Ａ１　実施医療機関と医薬品ＧＣＰ省令第３９条の２、医療機器ＧＣＰ省令第５９条又は再生医療等製品ＧＣＰ省令第５９条に基づく委受託契約を締結した配送業者、または、実施医療機関の治験協力者により、実施医療機関から被験者宅に治験薬等を配送することは可能である。その際、試験デザイン、治験薬等の性質、被験者の状態等を考慮の上、同意を得た被験者において実施医療機関の責任のもと実施すること。なお、運搬中の治験薬等の品質管理[illegible]への交付を確実に行うための手順を予め定めておくこと。また、[illegible]し保存すること。



Sponsors

Provides **alternative measures** that can be taken when the process predetermined in the **study protocol is not deemed feasible due to the COVID-19 situation**.

https://www.pmda.go.jp/english/int-activities/0002.pdf

Enables shipments of investigational medical products directly to patients' homes

Initially published on 27 March, 2020



新型コロナウイルス感染症の影響下での医薬品、医療機器及び再生医療等製品の治験実施に係るQ&Aについて

現在実施中の医薬品、医療機器及び再生医療等製品の治験において、新型コロナウイルス感染症の影響により治験実施計画書の規定及び通常の手順と異なる対応を取らざるを得ない場合は、被験者の安全確保を最優先とした上で、経緯及び対応の記録を残し、その妥当性について説明できるようにしてください。また、実施医療機関において疑義が生じる場合の対応については、まずは治験依頼者と協議・相談してください。

これまでにいただいたお問い合わせに対する回答を、以下にご紹介しますので参考としてください。なお、内容については、今後のお問い合わせに応じて更新いたします。

２０２０年３月２７日作成
２０２０年４月２日更新
２０２０年４月２１日更新

Ｑ１　実施医療機関に来院できない等により、被験者が治験薬、治験機器又は治験製品（以下「治験薬等」という。）を直接受け取れない場合、実施医療機関から被験者宅に配送してよいか。（実施医療機関・治験依頼者）

Ａ１　実施医療機関と医薬品ＧＣＰ省令第３９条の２、医療機器ＧＣＰ省令第５９条又は再生医療等製品ＧＣＰ省令第５９条に基づく委受託契約を締結した配送業者、または、実施医療機関の治験協力者により、実施医療機関から被験者宅に治験薬等を配送することは可能である。その際、試験デザイン、治験薬等の性質、被験者の状態等を考慮の上、同意を得た被験者において実施医療機関の責任のもと実施すること。なお、運搬中の治験薬等の品質管理に加え、被験者への交付を確実に行うための手順を予め定めておくこと。また、経緯及び対応の記録を作成し保存すること。

Ｑ１－２　実施中の治験において、治験薬等を被験者宅に速やかに配送する必要があるため、事前にすべての実施医療機関と配送業者の間で、上記Ａ１に示される医薬品ＧＣＰ省令第３９条の２等の委受託契約を締結することが難しい場合、治験依頼者が選定・契約する配送業者により配送してもよいか。（実施医療機関・治験依頼者）

Ａ１－２　実施医療機関と治験依頼者で協議し、至急の対応を要する場合においては可能である。ただし、治験薬等の品質管理や被験者の個人情報等の取扱いを含めた業務内容を適切に取



https://www.pmda.go.jp/english/int-activities/0002.pdf
https://www.pmda.go.jp/files/000235164.pdf

Electronic-Informed Consent in Clinical Trials

“Electronic-Informed Consent” will be an option in clinical trials soon.

- To accerelate subject enrollment to clinilal trials
  - Informed consent by video conference system
  - Obtaining a signature to Informed consent forms by electronic methods (e.g. Digital sign by tablet)

- Notification will be issued, and the following points will be explained:
  - Basic concept (securing subjects’ human rights and safety, scientific quality, and reliability etc.)
  - Points to consider (Identify verification, procedures etc.)


事 務 連 絡
令和２年４月７日

各都道府県衛生主管部（局）御中

厚生労働省医薬・生活衛生局医薬品審査管理課

厚生労働省医薬・生活衛生局医療機器審査管理課

治験における同意文書の保存に関する取扱いについて

治験に被験者となるべき者が参加する際には、「医薬品の臨床試験の実施の基準に関する省令」（平成９年厚生省令第28号。以下「医薬品ＧＣＰ省令」という。）第52条、「医療機器の臨床試験の実施の基準に関する省令」（平成17年厚生労働省令第36号。以下「医療機器ＧＣＰ省令」という。）第72条又は「再生医療等製品の臨床試験の実施の基準に関する省令」（平成26年厚生労働省令第89号。以下「再生医療等製品ＧＣＰ省令」という。）第72条に基づいて同意文書に日付を記載し、記名押印し、又は署名することとされており、当該署名等済み同意文書については、医薬品ＧＣＰ省令第41条、医療機器ＧＣＰ省令第61条又は再生医療等製品ＧＣＰ省令第61条により、実施医療機関の長により原資料として保存することとされています。

今般、新型コロナウイルス感染症を含め、感染性のある疾病に罹患した患者を対象に治験を行う場合で、治験実施計画書又は院内の規定により、署名等済み同意文書の保存が疾病の伝染性等の観点から困難である場合については、下記の通り取扱って差し支えないことをお知らせしますので、関係する治験の円滑な推進にご活用下さい。

Today's Topics

1.Major regulatory updates in Japan

2.Regulatory Cooperation in Asia

APEC/LSIF/RHSC
(Asia-Pacific Economic Cooperation–Life Sciences Innovation Forum–Regulatory Harmonization Steering Committee)

RHSC co-Chairs; Japan and the United States.

PWAs	Champion Economies
MRCT/GCP inspection	**Japan**, Thailand
Pharmacovigilance	Republic of Korea
Biotherapeutics	the United States
Advanced Therapies	Singapore, the United States
Good Registration Management (GRM)	**Taiwan**, **Japan**
Global Supply Chain Integrity	the United States
Medical Devices	**Japan**, the United States, Republic of Korea

Champion economies lead activities for Priority Work Areas (PWAs).

CoEs provide the training at PWAs for regulators in APEC region.

PMDA is **endorsed as Center of Excellences (CoEs) for "MRCT/GCP inspection", "Pharmacovigilance", and "Medical Device"** PWA to provide training seminars to promote regulatory convergence, capacity and cooperation.

Cooperation to promote Good Registration Management

GRM: A concept to promote an efficient registration process for medical products by promoting Good Review Practice (GRevP) and Good Submission Practice (GSubP) cooperatively.

PMDA-Asia Training Center GRM Seminars

Date	Location	Number of participants
Nov. 15-17, 2016	Taipei	28 participants from 10 countries/regions
Oct. 31-Nov. 2, 2017	Taipei	30 participants from 8 countries/regions
Sep.26-28, 2018	Taipei	29 from 11 countries/regions
Sep. 17-19, 2019	Taipei	27 from 10 countries/regions
Sep. 14-16, 2021	Online	28 from 7 countries/regions

Global Harmonization Working Party (GHWP)

http://www.ahwp.info/

Medical Device International Affairs WG

Medical Device International Affairs WG within PMDA launched

- **About this WG**
  This WG is to discuss issues including guidelines related to international regulatory harmonization of medical devices.

- **Established**
  August, 2022

- **Members**
  Office of Medical Devices I-II
  Office of Standards and Compliance for Medical Devices
  Office of Software as a Medical Device
  Office of In Vitro Diagnostics
  Office of Manufacturing Quality and Vigilance for Medical Devices
  Office of International Programs
  Office of Research Promotion

https://www.pmda.go.jp/english/rs-sb-std/rs/0026.html

-Capacity Building Activities at PMDA-
Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs （PMDA-ATC）

- Established in April, 2016.
- Endorsed as Centers of Excellence (CoE) of APEC-LSIF-RHSC.
- Promote capacity building and human resource development through training seminars for Asian regulators.

Action Policy of PMDA-ATC

Contribute to universal health coverage in Asia through developing a foundation for regulatory harmonization in the Asian region.

Visits sites and conducts lectures, case studies and practical trainings.

Provides trainings tailored to local needs for more people.



Japan

Invites Asian regulatory representatives and offers training seminars.

Shares Japanese knowledge and experiences in the regulation of pharmaceuticals and medical devices with Asian countries.

Training Seminars provided by ATC

Seminars held in FY2021 (open to all regulators)

Contents	Date	Location
Quality Control (Herbal Medicine)	June 22-24, 2021	Online
Good Registration Management (GRM)	September 14-16, 2021	Online
Pediatric Review*1	September 21-24, 2021	Online
Medical Devices Review*2	November 15-17, 2021	Online
Good Manufacturing Practice (GMP)	November 25-26, 2021	Online
Pharmaceuticals Review	December 6-8, 2021	Online
Multi-Regional Clinical Trial (MRCT)*2,*3	January 18-21, 2022	Online
Pharmacovigilance*2	January 31, February 2-4, 2022	Online

Seminars planned in FY2022 (open to all regulators)

Contents	Date	Location
Quality Control (Herbal Medicine)	August 23-25, 2022	Online
Pediatric Review*1	September 12-15, 2022	Online
Good Manufacturing Practice (GMP)	October 25-26, 2022	Online
Medical Devices Review*2	November 14-16, 2022	Online
Medical Devices Review	November 28-30, 2022	Online
Pharmaceuticals Review	December 6-8, 2022	Online
Multi-Regional Clinical Trial (MRCT)*2,*3 (PMDA-ATC with National Cancer Center MRCT Webinar 2022)	January 16-19, 2023	Online
Pharmacovigilance*2 (PMDA-ATC Pharmacovigilance Webinar 2023)	February 6-9, 2023	Online

*1 Joint Seminar with U.S.FDA, *2 APEC-LSIF-RHSC CoE Workshop, *3 Collaboration with National Cancer Center Japan

https://www.pmda.go.jp/english/int-activities/training-center/0004.html

PMDA-ATC Seminars in this fiscal year are offered as “Webinars” given the global impact of COVID-19

PMDA-ATC E-learning Contents

Training Materials

PMDA-ATC E-learning (YouTube)

The PMDA-ATC offers you videos on the current topics, introduction to the main services of PMDA and what we do to promote international regulatory harmonization.

Latest video Last updated: 2022.2.1

E-learning Contents

Category	Last updated	Note
1. Review	2021.12.1	added consultation service content
2. Safety	2020.10.31	added post-marketing safety content
3. Relief	2020.10.31	added "relief system for ADRs" content
4. Medical Device	2022.1.5	added COVID-19 test kit content
5. GXP	2021.9.1	added GCP content
6. PMDA Efforts *New!*	2022.2.1	added Chief Executive's message content

Review

1. Review Teams
2. Application Dossier
3. Review Process
4. Japanese Pharmacopoeia (JP)
5. Review of Generic Drugs
6. Review of Biosimilars
7. First-in-Human Studies
8. Review of Regenerative Medicinal Product
9. Expedited Regulatory Pathways in Japan
10. Consultation Service

E-learning Training Courses

Training Courses for specialized fields

The PMDA-ATC offers you videos regarding some specialized fields in the regulator-only website.
PMDA-ATC E-learning portal; https://www.pmda-atc-elearning.site/

To start the training courses, please register by the following steps;

1) Access to the application page, please fill in the form and submit it.
(https://www12.webcas.net/form/pub/pmda-atc/e-learning01)
2) Please select one course from the list on the application form and submit it.
3) If you wish to take multiple courses, please submit the application form for each course.
4) PMDA-ATC will send you Login ID and password normally within 5 business days.
5) The viewing period of one course is two months. You can watch it for 2 months starting from the date you received the e-mail to inform you of the start of the course.
Please note that your login ID will become invalid after 2 months.
6) A certificate of completion of the course can be issued.

Course List

Course	Duration	Last updated
1. Quality Control (Herbal Medicine)	108 min	2021.04.15
2. Medical Devices Review	134 min	2021.08.04
3. Pharmaceuticals Review	98 min	2021.08.31
4. Multi-Regional Clinical Trial (MRCT)	85 min	2021.10.20 *new*
5. Pharmacovigilance	135 min	2021.10.29 *new*

Apply for E-learning Training Courses *(Regulator only)*



‘Coming together is a beginning
Keeping together is progress
Working together is success’

By Henry Ford
(ICH 30th Anniversary Publication)

Thank you for your attention!

多謝